Novel paltform for the nasal delivery of proteins. Promising in-vivo results in EAE models.

Intra-nasal drug delivery

Highlights

• Drug efficiency in current treatment of MS is low.
• New way of administration and new drug combinations could improve MS therapy.

Our Innovation

• Intranasal drug delivery carrier for multiple sclerosis treatment agents. Efficient treatment through nasal administration with a new delivery carrier and a new drug combination.

Key Features

• The drug formulation based on the new carrier may be administered as nasal drops, spray, aerosol, nebuliser, or in a semi-solid preparation such as gel, cream or ointment
• Contains FDA approved ingredients

Development Milestones

• Pivotal study in humans
• Phase I/II clinical study

The Opportunity

• Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.

project-id 12-2007-1773

Patent pending and U.S. patent filed.
PCT publication number: WO/2007/043057